Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Morgan
Healthcare Conference
January 10, 2017
Spine &
CMF
9%
Dental
6%
Other
4%
Hips
24%
Knees
36%
Asia
Pacific
15%
Globally diverse
Americas
62%
(1) Based on preliminary full year revenue for 2016
*S.E.T. = Surgical, Sports Medicine, Foot & Ankle, Extremities and Trauma
S.E.T.
Spine &
CMF
Dental
*S.E.T. = Surgical, Sports Medicine, Foot & Ankle, Extremities and Trauma
Disciplined
Capital
Allocation
Leverage scale
Manufacturing and quality system optimization
Realize net synergies
History of Growth
Adj. EPS
Revenue ($MM)
$7.95
$10,000
$8.00
$7,684
Growth Drivers
$8,000
$6.00
$4.80
$6,000
$4.00
$4,452
$4,000
$2.00
$2,000
$0
$0.00
2011
2012
Revenue
2013
2014
2015
2016
Adjusted EPS
(1) As Adjusted and Revised. 2011 2012 as adjusted and revised EPS includes intangible asset amortization expense. 2013 2015 as
adjusted and revised EPS excludes intangible asset amortization. Reconciliations of these non-GAAP financial measures to the most directly
comparable GAAP measure are posted to our website: http://investor.zimmerbiomet.com
(2) 2016 financials are preliminary as described in press release dated January 10, 2017
7.6%
1,487M
market of ~$50B
9.3%
Utilization at a fraction of
developed market rates
2010
2020
2030
2040
2050
1,252M
Penetration opportunity in
developed markets
ShareProcedure
of World
Volume 14.2%
Growing
global
Population 65 and
Older
musculoskeletal
11.7%
969M
16.2%
714M
Increasing percentage of
population 65 and older
World Population
65 and Older
523M
Differentiated R&D
Developing meaningful
innovation
50 new products and solutions
launched in 2016
Disciplined M&A
Delivering value with
strategic acquisitions
Free cash flow generation
creates ongoing opportunities
Leading in Innovation
Joint
Preservation
Motion
Preservation
Personalized
Procedures
Innovating to
Minimize Complications
Diagnostics &
Infection
IMPROVED
QUALITY
OUTCOMES
MORE
EFFICIENT
CARE
INCREASED
PATIENT
VOLUME
VALUE
10
Musculoskeletal Health
Diversification
Platform Technologies
Hips
25%
Knee
36%
17%
11
Operational Efficiencies
Disciplined operating
expense and working
capital management
Leveraged Earnings
12
Dividends
Disciplined M&A
and Cap Ex investments
Committed dividend
program
Deleveraging
Committed to 2.5 x
2018 leverage target
Paid $1.0 B of Biomet
acquisition debt in 2016
Significant
Cash Flow
Generation
Flexibility
Project $2 billion+ in annual
Free Cash Flow by 2020
Enables long-term
value creation
13
IN SUMMARY
Built a Global
Leader
Successful,
Consistent
Strategy
Leading
Change in a
Dynamic
Industry
Delivering
Long-Term
Value
14
15